Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
ESALY Stock Summary
In the News
Alzheimer's Disease Drug Development: Another Lost Year
Investing in most current Alzheimer's drug companies is not recommended because they are not likely to modify the disease. Compounds that inhibit oxidative stress may only slow down the progression of Alzheimer's disease over the short term. Anavex's blarcamesine, Cyclo Therapeutics Trappsol Cyclo, Green Valley's GV-971, aromatherapy, and panax ginseng not only inhibit the formation of oxidants but scavenge them and reverse part of their damage.
Biogen Hits Buy Zone On A Fresh Win In Alzheimer's Disease; Eli Lilly, Eisai Shares Jump
Biogen stock jumped into a buy zone Thursday after Medicare officials said they would pay for some Alzheimer's treatments.
3 Stocks to Buy That Could Be the Next Biotech Breakthrough
In general, biotech stocks are not ideal for conservative investors. The companies in search of the next medical breakthrough are inherently risky.
Merck and Eisai report disappointing results from trials of combination treatment for melanoma and colorectal cancer
Merck MRK and its Japanese partner Eisai said Friday they are discontinuing the Phase 3 LEAP-003 trial evaluating Keytruda plus Lenvima for the first-line treatment of adults with unresectable or metastatic melanoma after data showed the combination did not produce an improvement in overall survival, or OS, compared with Keytruda alone. OS was one of two primary endpoints; the other, progression-free survival, did show a statistically significant improvement in an earlier interim analysis of data.
The Cream Of The Crop: 5 Biotech Stocks That Outrank 91% Of All Stocks
The top five biotech stocks today have several commonalities: strong ratings. Some also show promising charts and are Tech Leaders.
Eisai to Present Research from Oncology Portfolio at the Society of Gynecologic Oncology (SGO) 2023 Annual Meeting on Women's Cancer
Study Findings in Patients with Recurrent or Advanced Endometrial Carcinoma Who Were Rechallenged With Platinum Chemotherapy Will Be Featured in an Oral Plenary Session Additional Subgroup Analyses from the Pivotal Phase 3 Study 309/KEYNOTE-775 Trial May Provide Further Information About Treating Patients with Advanced Endometrial Carcinoma NUTLEY, N.J. , March 23, 2023 /PRNewswire/ -- Eisai will present two abstracts at the Society of Gynecologic Oncology (SGO) 2023 Annual Meeting on Women's Cancer (#SGOMtg), which is taking place in-person in Tampa, Florida and virtually from March 25-28.
FDA will review Eisai's and Biogen's Alzheimer's treatment Leqembi with decision on full approval expected in early July
Medicare has agreed to provide broader coverage once Leqembi receives full FDA approval.
Maker of promising Alzheimer's drug Leqembi expects full FDA approval this summer, expanded Medicare coverage
Even if the FDA grants full approval of the Alzheimer's treatment Leqembi, the rollout of the treatment will take years.
Alzheimer's drug Leqembi: Eisai U.S. president
Eisai U.S. President Ivan Cheung joins Yahoo Finance Live to discuss the latest news surrounding Alzheimer's treatment with Leqembi.
Eisai Co., Ltd. (ESALF) Q3 2022 Earnings Call Transcript
Eisai Co., Ltd. (OTCPK:ESALF) Q3 2022 Earnings Conference Call February 6, 2023 3:15 AM ET Company Participants Tatsuyuki Yasuno - Senior Vice President, Chief Financial Officer, Chief IR Officer Ivan Cheung - Senior Vice President, Global Alzheimer's Disease Officer, President, Americas Region Chairman & Chief Executive Officer, Eisai Inc. Akiko Nakahama - Vice President, Chief Portfolio Officer, AD Filing and Registration Japan/Asia Lead Quality Conference Call Participants Hidemaru Yamaguchi - Citigroup Global Markets Japan Inc. Motoya Kohtani - Nomura Securities Co., Ltd.
ESALY Financial details
ESALY Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-03-31
Metric | History | 2018-03-31 | 2019-03-31 | 2020-03-31 | 2021-03-31 | 2022-03-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 2.09K | 2.24K | 2.43K | 2.25K | 2.64K | |
Net income per share | 180.97 | 221.12 | 424.77 | 146.94 | 159.44 | |
Operating cash flow per share | 522.37 | 361.8 | 358.55 | 257.64 | 410.11 | |
Free cash flow per share | 436.04 | 265.44 | 183.34 | 124.57 | 268.98 | |
Cash per share | 1.01K | 1.03K | 892.33 | 868.69 | 1.08K | |
Book value per share | 2.07K | 2.19K | 2.37K | 2.45K | 2.61K | |
Tangible book value per share | 1.12K | 1.25K | 1.49K | 1.56K | 1.69K | |
Share holders equity per share | 2.07K | 2.19K | 2.37K | 2.45K | 2.61K | |
Interest debt per share | 614.72 | 489.97 | 318.84 | 318.35 | 336.85 | |
Market cap | 1726.53B | 1806.56B | 1738.67B | 1794.24B | 1633.48B | |
Enterprise value | 1629.15B | 1659.02B | 1574.37B | 1635.4B | 1418.74B | |
P/E ratio | 33.3 | 28.5 | 14.28 | 42.6 | 35.73 | |
Price to sales ratio | 2.88 | 2.81 | 2.5 | 2.78 | 2.16 | |
POCF ratio | 11.54 | 17.42 | 16.92 | 24.29 | 13.89 | |
PFCF ratio | 13.82 | 23.74 | 33.08 | 50.25 | 21.18 | |
P/B Ratio | 2.91 | 2.88 | 2.56 | 2.55 | 2.18 | |
PTB ratio | 2.91 | 2.88 | 2.56 | 2.55 | 2.18 | |
EV to sales | 2.72 | 2.58 | 2.26 | 2.53 | 1.88 | |
Enterprise value over EBITDA | 15.76 | 14.46 | 9.69 | 18.2 | 14.66 | |
EV to operating cash flow | 10.89 | 16 | 15.32 | 22.14 | 12.07 | |
EV to free cash flow | 13.04 | 21.8 | 29.96 | 45.8 | 18.4 | |
Earnings yield | 0.03 | 0.04 | 0.07 | 0.02 | 0.03 | |
Free cash flow yield | 0.07 | 0.04 | 0.03 | 0.02 | 0.05 | |
Debt to equity | 0.29 | 0.22 | 0.13 | 0.13 | 0.13 | |
Debt to assets | 0.17 | 0.13 | 0.08 | 0.08 | 0.08 | |
Net debt to EBITDA | -0.94 | -1.29 | -1.01 | -1.77 | -2.22 | |
Current ratio | 2.22 | 1.9 | 2.07 | 2.02 | 2.04 | |
Interest coverage | 26.04 | 55.3 | 85.84 | 38.06 | 34.51 | |
Income quality | 2.89 | 1.64 | 0.84 | 1.75 | 2.45 | |
Dividend Yield | 0.02 | 0.02 | 0.03 | 0.03 | 0.03 | |
Payout ratio | 0.83 | 0.68 | 0.38 | 1.09 | 1 | |
Sales general and administrative to revenue | 0.31 | 0.36 | 0.37 | 0.44 | 0.48 | |
Research and developement to revenue | 0.23 | 0.23 | 0.2 | 0.23 | 0.23 | |
Intangibles to total assets | 0.26 | 0.26 | 0.26 | 0.26 | 0.23 | |
Capex to operating cash flow | -0.17 | -0.27 | -0.49 | -0.52 | -0.34 | |
Capex to revenue | -0.04 | -0.04 | -0.07 | -0.06 | -0.05 | |
Capex to depreciation | -0.94 | -1.03 | -1.49 | -1.05 | -1.05 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
Graham number | 2.9K | 3.3K | 4.75K | 2.85K | 3.06K | |
ROIC | 0.07 | 0.08 | 0.16 | 0.05 | 0.06 | |
Return on tangible assets | 0.07 | 0.08 | 0.15 | 0.05 | 0.05 | |
Graham Net | -367.49 | -319.59 | -247.13 | -245.95 | -377.41 | |
Working capital | 294.24B | 265.94B | 269.44B | 262.33B | 327.27B | |
Tangible asset value | 321.18B | 357.82B | 427.85B | 447.52B | 484.32B | |
Net current asset value | 100.97B | 142.14B | 161.9B | 156.28B | 172.82B | |
Invested capital | 0.29 | 0.22 | 0.13 | 0.13 | 0.13 | |
Average receivables | 0 | 0 | 0 | 0 | 0 | |
Average payables | 69.42B | 72.81B | 77.2B | 85.71B | 101.31B | |
Average inventory | 81.9B | 74.41B | 66.81B | 75.43B | 92.06B | |
Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
Days payables outstanding | 123.5 | 153.38 | 159.72 | 213.94 | 225.61 | |
Days of inventory on hand | 146.78 | 134.31 | 136.56 | 192.6 | 206.7 | |
Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
Payables turnover | 2.96 | 2.38 | 2.29 | 1.71 | 1.62 | |
Inventory turnover | 2.49 | 2.72 | 2.67 | 1.9 | 1.77 | |
ROE | 0.09 | 0.1 | 0.18 | 0.06 | 0.06 | |
Capex per share | -86.33 | -96.36 | -175.21 | -133.07 | -141.13 |
Quarterly Fundamentals Overview
Last date of statement is 2022-12-31 for Q3
Metric | History | 2021-12-31 | 2022-03-31 | 2022-06-30 | 2022-09-30 | 2022-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 707.98 | 665.79 | 642.66 | 607.93 | 654.03 | |
Net income per share | 45.51 | -48.38 | 97.55 | 13.36 | 31.81 | |
Operating cash flow per share | 16.62 | 154.89 | 13.76 | -79.46 | -24.12 | |
Free cash flow per share | -20.31 | 127.21 | -41.66 | -96.31 | -49.02 | |
Cash per share | 904.6 | 1.08K | 1.01K | 925.77 | 937.9 | |
Book value per share | 2.56K | 2.61K | 2.81K | 2.89K | 2.7K | |
Tangible book value per share | 1.66K | 1.69K | 1.82K | 1.77K | 1.75K | |
Share holders equity per share | 2.56K | 2.61K | 2.81K | 2.89K | 2.7K | |
Interest debt per share | 315.07 | 332.73 | 332.41 | 332.47 | 525.6 | |
Market cap | 1867.09B | 1633.48B | 1628.45B | 2227.02B | 2527.71B | |
Enterprise value | 1698.59B | 1418.74B | 1435.53B | 2057.4B | 2409.83B | |
P/E ratio | 35.78 | -29.44 | 14.56 | 145.25 | 69.27 | |
Price to sales ratio | 9.2 | 8.56 | 8.84 | 12.77 | 13.48 | |
POCF ratio | 391.92 | 36.78 | 412.79 | -97.71 | -365.43 | |
PFCF ratio | -320.64 | 44.78 | -136.34 | -80.62 | -179.79 | |
P/B Ratio | 2.54 | 2.18 | 2.02 | 2.69 | 3.27 | |
PTB ratio | 2.54 | 2.18 | 2.02 | 2.69 | 3.27 | |
EV to sales | 8.37 | 7.43 | 7.79 | 11.8 | 12.85 | |
Enterprise value over EBITDA | 67.1 | -147.82 | 76.12 | 242.45 | 122.02 | |
EV to operating cash flow | 356.55 | 31.95 | 363.89 | -90.27 | -348.39 | |
EV to free cash flow | -291.7 | 38.9 | -120.19 | -74.48 | -171.41 | |
Earnings yield | 0.01 | -0.01 | 0.02 | 0 | 0 | |
Free cash flow yield | 0 | 0.02 | -0.01 | -0.01 | -0.01 | |
Debt to equity | 0.12 | 0.13 | 0.12 | 0.11 | 0.19 | |
Debt to assets | 0.08 | 0.08 | 0.07 | 0.08 | 0.12 | |
Net debt to EBITDA | -6.66 | 22.37 | -10.23 | -19.99 | -5.97 | |
Current ratio | 1.92 | 2.04 | 2.06 | 2.2 | 1.95 | |
Interest coverage | 38.08 | -36.94 | 22.25 | -3.13 | 15.53 | |
Income quality | 0.34 | -3.58 | 0.41 | 14.35 | -0.73 | |
Dividend Yield | 0.01 | 0 | 0.01 | 0 | 0.01 | |
Payout ratio | 1.76 | 0 | 0.82 | 0 | 2.52 | |
Sales general and administrative to revenue | 0.5 | 0.58 | 0.5 | 0.51 | 0.49 | |
Research and developement to revenue | 0.21 | 0.25 | 0.21 | 0.25 | 0.21 | |
Intangibles to total assets | 0.24 | 0.23 | 0.24 | 0.26 | 0.24 | |
Capex to operating cash flow | -2.22 | -0.18 | -4.03 | 0.21 | 1.03 | |
Capex to revenue | -0.05 | -0.04 | -0.09 | -0.03 | -0.04 | |
Capex to depreciation | -1.07 | -0.86 | -1.62 | -0.49 | -0.7 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
Graham number | 1.62K | 1.69K | 2.48K | 931.76 | 1.39K | |
ROIC | 0.02 | -0.01 | 0.03 | 0 | 0.01 | |
Return on tangible assets | 0.01 | -0.01 | 0.03 | 0 | 0.01 | |
Graham Net | -359.59 | -377.41 | -356.84 | -306.27 | -434.39 | |
Working capital | 282.06B | 327.27B | 319.05B | 318.84B | 296.44B | |
Tangible asset value | 474.8B | 484.32B | 520.66B | 508.15B | 500.47B | |
Net current asset value | 178.37B | 172.82B | 176.43B | 174.81B | 156.12B | |
Invested capital | 0.12 | 0.13 | 0.12 | 0.11 | 0.19 | |
Average receivables | 0 | 0 | 0 | 0 | 0 | |
Average payables | 83.46B | 99.35B | 102.09B | 86.47B | 72.85B | |
Average inventory | 91.28B | 95.76B | 101.26B | 108.96B | 117.64B | |
Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
Days payables outstanding | 184.47 | 191.69 | 182.46 | 153.2 | 132.63 | |
Days of inventory on hand | 188.28 | 175.62 | 196.52 | 228.15 | 232.75 | |
Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
Payables turnover | 0.49 | 0.47 | 0.49 | 0.59 | 0.68 | |
Inventory turnover | 0.48 | 0.51 | 0.46 | 0.39 | 0.39 | |
ROE | 0.02 | -0.02 | 0.03 | 0 | 0.01 | |
Capex per share | -36.93 | -27.67 | -55.42 | -16.84 | -24.9 |
ESALY Frequently Asked Questions
What is Eisai Co., Ltd. stock symbol ?
Eisai Co., Ltd. is a JP stock and trading under the symbol ESALY
What is Eisai Co., Ltd. stock quote today ?
Eisai Co., Ltd. stock price is $- today.
Is Eisai Co., Ltd. stock public?
Yes, Eisai Co., Ltd. is a publicly traded company.